Engineered immune cells for patients awaiting stem cell transplant
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy that targets two proteins on harmful antibodies that can cause transplant rejection. It may help patients who have these antibodies and are planning a stem cell transplant from a half-matched donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 3 years old or older.
- You are planning to receive a stem cell transplant from a half-matched family donor.
- You do not have a fully matched donor available.
- Your blood test shows a high level of antibodies that can attack the donor cells (DSA level ≥5000 MFI).
- Your major organs (like liver and kidneys) are working well enough, and you do not have serious heart problems or infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
This trial tests a new treatment using immune cells from donated umbilical cord blood to fight a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The cells are engineered to target and kill cancer cells, which may help even if other treatments haven't worked.
This trial tests a new immune cell treatment (called CAR-T) that has been modified to help the cells stay active longer. It is designed for adults with B-cell leukemia or lymphoma who cannot tolerate strong chemotherapy, offering a potentially gentler option.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Hear when a new Transplantation Candidates With Hematological Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.